Scientific Evidence
CELLshot's technology is supported by over 36 peer-reviewed papers,
international regulatory registrations, and clinical data.
Academic Publications
Nature (2015)
p63⁺Krt5⁺ distal airway stem cells are essential for lung regeneration
DOI: 10.1038/nature13903Science Translational Medicine (2024)
Autologous transplantation of P63⁺ lung progenitor cells for COPD therapy
DOI: 10.1126/scitranslmed.adi3360Science (2020)
Exosomes: biogenesis, biological function and therapeutic potential
DOI: 10.1126/science.aau6977MISEV2018
Guidelines for extracellular vesicle researchers — international consensus by 500+ researchers worldwide
DOI: 10.1080/20013078.2018.1535750Regulatory Registrations
Japan JCIA Registration
Registration No: 22788 — Human Endometrial Stem Cell Exosomes (exclusive listing in Japan)
US INCI Registration
Mono ID: 39006 — Human Endometrial Stem Cell Exosomes (exclusive US INCI registration)
Quality Standards
GESS
Global Exosome Safety Standard — founder of global exosome safety standards
GMP Standard
Manufactured on GMP-certified production lines — achieving high purity (>99.9%) and high bioactivity
Clinical Data
Human Efficacy Trial
Report No: HZ-F-2500025 — 19.40% reduction in nasolabial fold volume, 34.47% improvement in skin elasticity at 28 days
SGS Patch Test
33 sensitive-skin subjects — no skin irritation observed in the majority of participants
Clinical Trial Results
28 Days
Trial Duration
19.4%
Nasolabial Fold Volume Improvement
34.5%
Skin Elasticity Improvement
The complete evidence chain of 36 papers is available on the tiptop platform.
tiptop Full Paper Archive →
※ CELLshot is a cosmetic product. It is not a pharmaceutical or medical device and is not intended to treat, diagnose, or prevent any disease.
※ The research data presented is based on academic literature and does not guarantee individual results.